Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza.
Sponsor: BioCryst Pharmaceuticals
Terminated
This study was terminated for administrative reasons.
Other terminated trials from BioCryst Pharmaceuticals
This PHASE3 trial investigates Influenza and is currently terminated or withdrawn. BioCryst Pharmaceuticals leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Apr 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioCryst Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .